- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Top Growth Stocks
U.S. Pharmaceuticals & Biotech Top Growth Stocks
Results
34
34 companies
Axsome Therapeutics
Market Cap: US$6.2b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$125.17
7D
3.2%
1Y
34.3%
Zevra Therapeutics
Market Cap: US$501.3m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$8.95
7D
-1.3%
1Y
22.3%
Legend Biotech
Market Cap: US$6.5b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$36.08
7D
3.9%
1Y
-25.3%
Vanda Pharmaceuticals
Market Cap: US$274.2m
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
VNDA
US$4.61
7D
-2.5%
1Y
-8.2%
LENZ Therapeutics
Market Cap: US$1.1b
Operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.
LENZ
US$41.98
7D
8.7%
1Y
76.4%
Evoke Pharma
Market Cap: US$11.0m
Operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.
EVOK
US$5.21
7D
-4.4%
1Y
34.6%
ARS Pharmaceuticals
Market Cap: US$1.1b
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
SPRY
US$10.07
7D
-13.3%
1Y
-11.4%
Madrigal Pharmaceuticals
Market Cap: US$9.6b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$432.89
7D
-1.1%
1Y
77.5%
Soleno Therapeutics
Market Cap: US$3.7b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$69.77
7D
3.1%
1Y
43.7%
Achieve Life Sciences
Market Cap: US$142.6m
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
ACHV
US$2.83
7D
-5.0%
1Y
-32.1%
ACADIA Pharmaceuticals
Market Cap: US$4.3b
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
ACAD
US$25.26
7D
-2.8%
1Y
57.2%
ADMA Biologics
Market Cap: US$4.0b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$16.87
7D
-2.3%
1Y
3.8%
Eton Pharmaceuticals
Market Cap: US$479.2m
A pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
ETON
US$17.67
7D
2.1%
1Y
285.0%
AC Immune
Market Cap: US$212.7m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$2.28
7D
11.8%
1Y
-23.7%
Arcutis Biotherapeutics
Market Cap: US$1.9b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$17.15
7D
10.5%
1Y
65.5%
Grace Therapeutics
Market Cap: US$42.3m
Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
GRCE
US$3.20
7D
5.6%
1Y
32.8%
CorMedix
Market Cap: US$955.5m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$12.40
7D
-16.4%
1Y
115.3%
SIGA Technologies
Market Cap: US$607.9m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$8.42
7D
0.4%
1Y
9.2%
Invivyd
Market Cap: US$194.5m
A biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
IVVD
US$1.14
7D
17.2%
1Y
40.0%
Neuphoria Therapeutics
Market Cap: US$22.4m
A clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia.
NEUP
US$11.89
7D
4.9%
1Y
n/a
Harmony Biosciences Holdings
Market Cap: US$2.1b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
HRMY
US$35.99
7D
-2.4%
1Y
1.1%
Iovance Biotherapeutics
Market Cap: US$796.1m
A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.
IOVA
US$2.49
7D
11.7%
1Y
-75.1%
Ardelyx
Market Cap: US$1.6b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$6.52
7D
2.5%
1Y
16.4%
Krystal Biotech
Market Cap: US$4.3b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$150.27
7D
1.7%
1Y
-18.4%
Unicycive Therapeutics
Market Cap: US$76.3m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$4.36
7D
4.1%
1Y
23.1%
BeOne Medicines
Market Cap: US$35.1b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$341.80
7D
11.7%
1Y
78.7%
Evaxion
Market Cap: US$17.0m
A clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.
EVAX
US$2.92
7D
6.2%
1Y
-83.1%
Earth Science Tech
Market Cap: US$59.3m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.20
7D
0%
1Y
24.9%
Journey Medical
Market Cap: US$185.7m
Focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$7.01
7D
-2.8%
1Y
49.8%
Day One Biopharmaceuticals
Market Cap: US$759.0m
A commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.
DAWN
US$7.55
7D
0.5%
1Y
-46.8%
Celcuity
Market Cap: US$2.3b
A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
CELC
US$55.69
7D
8.7%
1Y
269.8%
Avadel Pharmaceuticals
Market Cap: US$1.5b
Operates as a biopharmaceutical company in the United States.
AVDL
US$15.76
7D
6.8%
1Y
8.8%
Zai Lab
Market Cap: US$3.3b
A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
ZLAB
US$30.76
7D
-7.1%
1Y
55.0%
Geron
Market Cap: US$880.5m
A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
GERN
US$1.40
7D
0%
1Y
-67.1%